Brokers Set Expectations for RARE FY2026 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Equities researchers at HC Wainwright issued their FY2026 earnings estimates for Ultragenyx Pharmaceutical in a research report issued on Thursday, November 5th. HC Wainwright analyst R. Selvaraju expects that the biopharmaceutical company will earn ($1.51) per share for the year. HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($3.21) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q4 2026 earnings at $2.35 EPS, Q1 2027 earnings at $0.63 EPS, Q2 2027 earnings at $1.38 EPS, Q3 2027 earnings at $1.73 EPS, Q4 2027 earnings at $2.64 EPS and FY2027 earnings at $6.38 EPS.

A number of other brokerages have also recently weighed in on RARE. Canaccord Genuity Group reduced their target price on Ultragenyx Pharmaceutical from $39.00 to $34.00 and set a “buy” rating on the stock in a report on Wednesday, November 4th. Royal Bank Of Canada lowered Ultragenyx Pharmaceutical from a “moderate buy” rating to a “hold” rating in a research note on Thursday, September 3rd. Jefferies Financial Group cut their price objective on Ultragenyx Pharmaceutical from $77.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, September 3rd. Morgan Stanley raised their price objective on Ultragenyx Pharmaceutical from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 4th. Finally, TD Cowen lifted their price objective on Ultragenyx Pharmaceutical from $18.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $29.79.

Ultragenyx Pharmaceutical Stock Performance

RARE stock opened at $16.14 on Monday. The business has a fifty day simple moving average of $15.65 and a 200-day simple moving average of $22.64. Ultragenyx Pharmaceutical has a 52 week low of $12.73 and a 52 week high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.06). The business had revenue of $173.00 million for the quarter, compared to the consensus estimate of $182.49 million. During the same quarter in the previous year, the business posted ($1.81) EPS. The firm’s revenue was up 8.2% compared to the same quarter last year.

Institutional Trading of Ultragenyx Pharmaceutical

A number of institutional investors have recently added to or reduced their stakes in RARE. BlackRock Inc. acquired a new stake in Ultragenyx Pharmaceutical in the 2nd quarter valued at $355,746,000. Bank of America Corp DE acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth about $38,347,000. Jefferies Financial Group Inc. acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth about $31,040,000. Eagle Health Investments LP acquired a new position in shares of Ultragenyx Pharmaceutical during the first quarter worth about $18,522,000. Finally, Palo Alto Investors LP acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth about $19,916,968. 97.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 7,066 shares of the firm’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $15.27, for a total value of $107,897.82. Following the transaction, the chief financial officer owned 89,229 shares of the company’s stock, valued at approximately $1,362,526.83. This trade represents a 7.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 8,510 shares of company stock valued at $127,561. Company insiders own 5.20% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company works on therapies for conditions with limited treatment options, including enzyme deficiencies and metabolic disorders. Its marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii (vestronidase alfa), for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), for long-chain fatty acid oxidation disorders.